Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? - Wikidata - wikimedia - TriplyDB

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

http://www.wikidata.org/entity/Q36291489

about

Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.

P2860

Q47261072-04E8BC95-BE64-4140-A69C-376A17DC7165

P2860

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

http://www.wikidata.org/entity/Q36291489

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

@ast

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

@en

type

label

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

@ast

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

@en

prefLabel

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

@ast

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

@en

P1433

Q36291489-75DBA905-B7BC-480D-9884-A18E99904E29

P1476

Q36291489-9590227A-09FD-4D8B-93FB-6761674CBE74

P2093

Q36291489-056AC791-0CA2-4DFE-BFE6-C357834C3F56

Q36291489-06D4224E-570B-4305-B8DA-8F10FE008C3D

Q36291489-275042DD-0BC3-48D8-BD50-06518179164F

Q36291489-79D61B49-6CD1-4CC9-83B8-277ED90A74D8

Q36291489-808C2BF4-48F1-44A0-A21B-F4590216E133

Q36291489-A2554A94-430A-4505-8C60-306EAF65B981

Q36291489-D3C3080D-5E0A-486F-A4D3-DA08293D814B

Q36291489-E9129BF5-4024-443B-9B92-6D1D701C12A3

Q36291489-F0E3D034-580F-42FA-B727-C0878B4B2E32

Q36291489-FF873BF7-3B87-478F-BE56-7EEA43CA083F

P2860

Q36291489-074CC389-AD26-446B-A357-9C323B8DDC0B

Q36291489-2526249A-F4B8-40FA-9E54-6ACD244C484D

Q36291489-3991D56A-53C0-4E61-9428-C0E05E7FCB25

Q36291489-469BFBC1-7998-41F1-81B1-389FAEEB1F60

Q36291489-4AE3DC3B-CC4F-49BC-8C1E-E7F870719FB4

Q36291489-4BF7F36A-DC7E-4683-B98C-0E0042E90CBE

Q36291489-676392BF-C6A6-4533-98F1-45A22B1A2B94

Q36291489-6DA9A742-EC9F-44B5-BAA0-DFABEC7BA7B3

Q36291489-738B4E46-84E7-46F7-B3E1-43B999F5F082

Q36291489-7B016F82-7436-4033-A492-0B0B420CB5CA

P304

Q36291489-21CADA88-6EC0-4AC7-B086-C3972EB78876

P31

Q36291489-B982F35B-D81F-454A-A2F0-E63BE30359BC

P356

Q36291489-C7215901-A359-4FB1-A501-C3900888E2FC

P407

Q36291489-D84473E1-A605-43EA-8CA6-4D16007CB6CA

P433

Q36291489-C1B05621-115A-4136-8193-E0407A47969F

P478

Q36291489-F66A46BA-7CAB-4943-B708-5EA75AA18CC5

P50

Q36291489-64771FFB-10D8-4425-B382-2A01920C1A71

Q36291489-8BFD195A-EE17-464D-AF3C-8D80E672A7A4

P577

Q36291489-8A628B0D-9556-4727-8488-231B22406655

P698

Q36291489-25985CF5-56FC-4F09-96C5-FB647E51CD29

P932

Q36291489-65DA8874-F5B2-4D5E-92DF-0FE2C6507052

P356

JOURNAL.PONE.0172341

P1433

P1476

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

@en

P2093

Haruki Kume

http://www.w3.org/2001/XMLSchema#string

Hideyo Miyazaki

http://www.w3.org/2001/XMLSchema#string

Hiroshi Fukuhara

http://www.w3.org/2001/XMLSchema#string

Masafumi Otsuka

http://www.w3.org/2001/XMLSchema#string

Satoru Taguchi

http://www.w3.org/2001/XMLSchema#string

Teppei Morikawa

http://www.w3.org/2001/XMLSchema#string

Tetsuya Fujimura

http://www.w3.org/2001/XMLSchema#string

Tohru Nakagawa

http://www.w3.org/2001/XMLSchema#string

Yasuhiko Igawa

http://www.w3.org/2001/XMLSchema#string

Yukio Homma

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (D

Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group.

Systemic adjuvant therapies in renal cell carcinoma

Adjuvant therapy of renal cell carcinoma.

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.

Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma.

The use of interferon in melanoma patients: a systematic review.

Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC).

Role of targeted therapy in combination with surgery in renal cell carcinoma.

P304

e0172341

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0172341

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Sebastiano Buti

Melissa Bersanelli

P577

2017-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28241027

http://www.w3.org/2001/XMLSchema#string

P932

5328261

http://www.w3.org/2001/XMLSchema#string